logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Mental Health, Drug Abuse and Learning Difficulties

Results

Drugs

June 2020

Abilify MyCite (aripiprazole with sensor) for bipolar disorder and schizophrenia

Abilify MyCite is a drug-device combination comprising aripiprazole embedded with an Ingestible Event Marker (IEM) sensor. The aripiprazole attaches in the brain to receptors which help normalise the activity of the brain. The drug is packaged within an innovative system which helps patients (and healthcare workers) monitor when the medication is taken through integration with a sensor patch and app. Abilify MyCite is different to other ways of monitoring whether medication has been taken because it gives results of the actual medication taken, without need for blood or urine samples, as opposed to an estimate and if licensed, will offer an additional treatment option for patients with BP1 and SCH.

Drugs

February 2019

Esketamine (nasal spray) for major depressive disorder with imminent risk of suicide

Esketamine nasal spray is being developed as a treatment that could be given to people with depression with an imminent risk of suicide. Major depressive disorder (often called depression or major depression in UK) is a serious mood disorder that can impact all aspects of daily life. Symptoms can include low mood, weight changes, lack of energy, disturbed sleep, and suicidal intentions and thoughts. The time between suicidal thoughts and attempted suicide is often very short, and so there is a need for urgent intervention and treatment.

Drugs

January 2019

Brexanolone for postpartum depression

Brexanolone is an active product of the female reproductive hormone progesterone that regulates a specific neurotransmitter involved in a range of behaviours, including the stress
response. Some small studies have shown that brexanolone rapidly and significantly improves the symptoms of PPD and other hormonal mood disorders when compared to
other treatments. If licensed brexanolone would be the first PPD treatment that specifically targets the underlying disease process in PPD.

Drugs

January 2018

Naloxone Auto-injector (Evzio) for Opioid Substance Use Disorder

Evzio is being developed as an injectable device that contains naloxone, a drug used to reverse the effects of opioid drug overdose. It is designed to be easily administered by non-health professionals in a non-clinical setting. If licensed it has the potential to improve emergency responses to opioid overdoses as it can be used in the home environment, enabling caregivers to respond quickly and confidently due to the voice and visual guidance provided with the device.

Drugs

December 2017

Esketamine for Treatment-resistant Depression

Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults.

Drugs

May 2017

Lumateperone for acute exacerbations of psychosis in schizophrenia

Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than current antipsychotic medication.If licensed lumateperone may provide an alternative treatment …

Devices

March 2017

Monarch™ External Trigeminal Nerve Stimulation (eTNS) System for attention deficit hyperactive disorder (ADHD)

The Monarch™ external trigeminal nerve stimulation system (eTNS system) is a non-invasive device to treat attention deficit hyperactive disorder (ADHD) in children, young people and adults aged seven years and above. People with ADHD have behavioural symptoms including inattentiveness, hyperactivity and impulsiveness. Medicines used to treat ADHD have lots of side-effects and are only used …

Reviews

January 2017

SUMMARY – Emerging technologies for the diagnosis, treatment and management of epilepsy

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review of new technologies that are being developed for the diagnosis, treatment and management of epilepsy. Epilepsy is a common neurological condition that affects around 600,000 people in the UK (equivalent to almost 1 in 100 people). It causes sudden and unprovoked …

Reviews

January 2017

REVIEW – Emerging technologies for the diagnosis, treatment and management of epilepsy

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review of new technologies that are being developed for the diagnosis, treatment and management of epilepsy. Epilepsy is a common neurological condition that affects around 600,000 people in the UK (equivalent to almost 1 in 100 people). It causes sudden and unprovoked …

Drugs

September 2016

Diazoxide choline controlled-release for Prader-Willi syndrome – first line

Diazoxide choline is a new drug to treat Prader-Willi syndrome. Prader-Willi syndrome is a rare genetic disorder that causes people to eat uncontrollably and become obese. It may also cause learning difficulties and behavioural problems. Diazoxide choline is a slow release tablet that is taken by mouth. Some studies have suggested that diazoxide choline may …

Get Alerts